loading
Schlusskurs vom Vortag:
$62.69
Offen:
$63.15
24-Stunden-Volumen:
29,909
Relative Volume:
0.20
Marktkapitalisierung:
$688.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.00%
1M Leistung:
+15.24%
6M Leistung:
+164.52%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$61.71
$63.20
1-Wochen-Bereich:
Value
$57.33
$65.57
52-Wochen-Spanne:
Value
$11.17
$65.57

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name
Firmenname
Palvella Therapeutics Inc
Name
Telefon
(484) 253-1461
Name
Adresse
125 STRAFFORD AVE, WAYNE
Name
Mitarbeiter
14
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
PVLA's Discussions on Twitter

Vergleichen Sie PVLA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PVLA
Palvella Therapeutics Inc
62.24 693.33M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
403.23 100.41B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
606.00 59.59B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
459.72 59.77B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
768.60 45.14B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
343.08 37.42B 3.81B -644.79M -669.77M -6.24

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-09 Eingeleitet Oppenheimer Outperform
2025-08-06 Eingeleitet Raymond James Outperform
2025-07-21 Eingeleitet Truist Buy
2025-04-09 Eingeleitet Chardan Capital Markets Buy
2025-03-26 Eingeleitet Stifel Buy
2025-03-07 Eingeleitet Scotiabank Sector Outperform
2025-02-20 Eingeleitet Canaccord Genuity Buy
2025-02-05 Eingeleitet TD Cowen Buy
2024-12-26 Eingeleitet H.C. Wainwright Buy
2024-12-18 Eingeleitet Cantor Fitzgerald Overweight
2020-03-13 Hochstufung Robert W. Baird Neutral → Outperform
2019-07-30 Herabstufung Robert W. Baird Outperform → Neutral
2019-05-14 Eingeleitet Robert W. Baird Outperform
2018-03-19 Eingeleitet Evercore ISI Outperform
2018-03-19 Eingeleitet Jefferies Buy
2018-01-16 Bestätigt H.C. Wainwright Buy
2017-05-30 Eingeleitet Rodman & Renshaw Buy
2016-08-05 Fortgesetzt ROTH Capital Buy
2015-08-12 Eingeleitet JMP Securities Mkt Outperform
2015-07-27 Eingeleitet Oppenheimer Outperform
2015-07-22 Eingeleitet ROTH Capital Buy
Alle ansehen

Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten

pulisher
05:48 AM

Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returns2025 Bull vs Bear & Consistent Income Trade Recommendations - newser.com

05:48 AM
pulisher
Sep 30, 2025

Can Palvella Therapeutics Inc. (PI6) stock attract ESG investmentsWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Will Palvella Therapeutics Inc. bounce back from current supportWeekly Trend Report & Safe Swing Trade Setups - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthSwing Trade & Technical Pattern Based Buy Signals - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Tick level data insight on Palvella Therapeutics Inc. volatilityEarnings Beat & Weekly High Potential Stock Alerts - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

How to interpret RSI for Palvella Therapeutics Inc. stockJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com

Sep 30, 2025
pulisher
Sep 30, 2025

Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year High Following Analyst Upgrade - Defense World

Sep 30, 2025
pulisher
Sep 29, 2025

Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week High After Analyst Upgrade - MarketBeat

Sep 29, 2025
pulisher
Sep 29, 2025

Published on: 2025-09-29 15:57:39 - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

How to build a custom watchlist for Palvella Therapeutics Inc.Trade Analysis Report & Risk Managed Trade Strategies - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Published on: 2025-09-29 09:58:44 - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas - MyChesCo

Sep 29, 2025
pulisher
Sep 29, 2025

Published on: 2025-09-29 07:36:24 - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Equities Analysts Offer Predictions for PVLA FY2028 Earnings - Defense World

Sep 29, 2025
pulisher
Sep 28, 2025

Published on: 2025-09-28 21:37:00 - newser.com

Sep 28, 2025
pulisher
Sep 28, 2025

Palvella Therapeutics Inc Stock Analysis and ForecastVolume Spike Alerts & Budget Friendly Portfolio - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations - MyChesCo

Sep 28, 2025
pulisher
Sep 28, 2025

What analysts say about Palvella Therapeutics Inc stockHealthcare Stock Analysis & Minimal Investment Capital - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

Palvella Expands QTORIN Gel Program for Rare Disease - MSN

Sep 27, 2025
pulisher
Sep 27, 2025

Best data tools to analyze Palvella Therapeutics Inc. stockPortfolio Return Report & Real-Time Market Sentiment Alerts - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Published on: 2025-09-27 05:34:37 - newser.com

Sep 27, 2025
pulisher
Sep 27, 2025

Applying big data sentiment scoring on Palvella Therapeutics Inc.Analyst Downgrade & Long Hold Capital Preservation Tips - newser.com

Sep 27, 2025
pulisher
Sep 26, 2025

Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $73.00 at Chardan Capital - MarketBeat

Sep 26, 2025
pulisher
Sep 26, 2025

Chardan Capital Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq

Sep 26, 2025
pulisher
Sep 26, 2025

Chardan Raises Price Target on Palvella Therapeutics to $73 From $60, Keeps Buy Rating - MarketScreener

Sep 26, 2025
pulisher
Sep 26, 2025

Goldman Sachs Group Inc. Makes New $533,000 Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Sep 26, 2025
pulisher
Sep 25, 2025

HC Wainwright & Co. Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq

Sep 25, 2025
pulisher
Sep 25, 2025

Palvella Therapeutics stock price target raised to $70 at Jones Trading - Investing.com UK

Sep 25, 2025
pulisher
Sep 24, 2025

Palvella to develop therapy for rare skin condition with no approved treatments By Investing.com - Investing.com South Africa

Sep 24, 2025
pulisher
Sep 24, 2025

Stifel Maintains 'Buy' Rating and Raises Price Target for PVLA t - GuruFocus

Sep 24, 2025
pulisher
Sep 24, 2025

Stifel Nicolaus Increases Palvella Therapeutics (NASDAQ:PVLA) Price Target to $80.00 - MarketBeat

Sep 24, 2025
pulisher
Sep 24, 2025

Palvella Therapeutics stock price target raised to $80 by Stifel on new skin treatment - Investing.com Canada

Sep 24, 2025
pulisher
Sep 24, 2025

Palvella Therapeutics stock price target raised to $90 from $85 at Oppenheimer - Investing.com UK

Sep 24, 2025
pulisher
Sep 24, 2025

Palvella to develop therapy for rare skin condition with no approved treatments - Investing.com Canada

Sep 24, 2025

Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)

Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$35.80
price up icon 1.62%
$85.78
price up icon 1.20%
$31.39
price up icon 2.31%
$102.62
price up icon 4.05%
$144.32
price up icon 0.43%
biotechnology ONC
$343.34
price up icon 0.53%
Kapitalisierung:     |  Volumen (24h):